NASH Clinical Trials
Here are the 6 most popular medical studies for nash
Caspase Inhibitor
Emricasan for Cirrhosis
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.
HMG-CoA Reductase Inhibitor
Statins for Non-alcoholic Steatohepatitis (NASH)
This trial will test whether or not a daily dose of atorvastatin (a type of statin) is effective in treating NASH and hepatic fibrosis, and whether it is safe. The results of this study will help design a larger study on the matter.
Popular filter options for nash trials
Non-alcoholic Fatty Liver Disease Clinical Trials
View 49 Non-alcoholic Fatty Liver Disease medical studies.
Monoclonal Antibodies
GSK4532990 for Non-alcoholic Fatty Liver Disease
This trial aims to investigate how the drug GSK4532990 is processed in the body and how it affects the liver. The study will also assess the safety and tolerability of the drug. Participants
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Thyroid hormone receptor agonist
MGL-3196 for Non-alcoholic Fatty Liver Disease
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in patients with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
NAFLD Clinical Trials
View 48 NAFLD medical studies.
Monoclonal Antibodies
GSK4532990 for Non-alcoholic Fatty Liver Disease
This trial aims to investigate how the drug GSK4532990 is processed in the body and how it affects the liver. The study will also assess the safety and tolerability of the drug. Participants
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Thyroid hormone receptor agonist
MGL-3196 for Non-alcoholic Fatty Liver Disease
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in patients with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Phase 3 Nash Clinical Trials
View 57 phase 3 nash medical studies.
Hormone Therapy
Estrogen Therapy for NASH in Postmenopausal Women
This trial will study the effect of the hormone estradiol on non-alcoholic steatohepatitis (NASH) in post-menopausal women. NASH is a growing epidemic in the United States with limited treatment options.
Glucagon-like peptide-1 receptor agonist
Semaglutide for Non-alcoholic Steatohepatitis
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Nash Clinical Trials With No Placebo
View 57 nash medical studies that do not have a placebo group.
Monoclonal Antibodies
GSK4532990 for Non-alcoholic Fatty Liver Disease
This trial aims to investigate how the drug GSK4532990 is processed in the body and how it affects the liver. The study will also assess the safety and tolerability of the drug. Participants
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Microbiota Therapy
Fecal Microbiota Transplantation for Non-alcoholic Fatty Liver Disease
Nonalcoholic steatohepatitis (NASH) is common, may progress to cirrhosis and is predicted to become a leading indication for liver transplantation in the near future. Though often associated with obesity and the metabolic syndrome, our current understanding of disease development is limited and there are few therapeutic options. Imbalance of gut bacteria is suspected to play a key role driving the progression of fatty liver disease and there is hope manipulation of these bacteria may be beneficial. This study will determine if fecal microbiota transplantation, using stool from lean donors, is an effective and safe treatment for NASH.
Behavioural Intervention
Weight Loss for Obesity and Metabolic Syndrome
This trial is investigating how fat is stored in organs, and why this impacts some people's health more than others. The findings could lead to better treatments for diabetes and cardiovascular disease.
Thiazolidinedione
Rosiglitazone for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the efficacy of rosiglitazone alone compared with rosiglitazone plus metformin or rosiglitazone plus losartan in the treatment of biopsy proven nonalcoholic steatohepatitis (NASH). This study was designed to answer the question: are there differences in the efficacy (as measured by histopathology and insulin resistance) of three different therapeutic modalities used to treat NASH?
View More Nash Trials
See another 33 medical studies focused on nash.
Frequently Asked Questions
Introduction to nash
What are the top hospitals conducting nash research?
In the realm of clinical trials for Nonalcoholic Steatohepatitis (NASH), several hospitals have emerged as key players in the battle against this complex liver condition. Located in Lakewood Ranch, Florida, the Florida Research Institute takes a leading role with six active NASH trials and an impressive total of 17 trials dedicated to this disease. Having initiated their first trial in 2016, they are committed to exploring innovative treatment options for patients affected by NASH. Similarly, South Texas Research Institute in Edinburg has also made significant strides with six ongoing NASH trials and a commendable history of 14 completed studies since recording their inaugural trial just two years ago in 2019.
Meanwhile, at Inland Empire Liver Foundation situated in Rialto, California researchers are actively engaged in six NASH clinical trials while having conducted an extensive range of 28 previous investigations since initiating their first one back in 2015. Another prominent player on this list is Tandem Clinical Research located in Marrero which currently runs six active NASH trials alongside a substantial contribution to scientific knowledge through conducting thirteen previous studies; theirs can be traced back only four years ago to2017.The American Research Corporation located within San Antonio may appear slightly smaller-scale but nevertheless plays a crucial part with its five current NASH clinical trials and noteworthy involvement through eleven previously held investigations that began around the same time frame.
These top hospitals spearhead efforts not only to understand and combat NASH but also signify triumphs of medical advancement on both regional and national levels. Each step taken towards unraveling the intricacies surrounding this liver condition brings us closer to discovering effective treatments that could positively impact countless lives worldwide
Which are the best cities for nash clinical trials?
For NASH clinical trials, several cities emerge as top contenders in the field of research and development. San Antonio, Texas leads with an impressive 69 active trials focusing on promising treatments like TERN-501, TVB-2640, and AXA1125. Following closely behind is Miami, Florida with 56 ongoing studies exploring IVA337, Study 1 ALN-HSD Low Dose, Obeticholic Acid, among others. Houston, Texas also plays a notable role in NASH research with 30 active trials investigating TERN-501, TVB-2640, BOS-580 and more. These cities provide crucial platforms for individuals seeking to participate in cutting-edge NASH clinical trials that pave the way for advancements in therapy options and potential breakthroughs in care.
Which are the top treatments for nash being explored in clinical trials?
Cutting-edge research in clinical trials is shedding light on the top treatments for non-alcoholic steatohepatitis (NASH), a liver disease with limited therapeutic options. Two leading contenders include EFX and empagliflozin. EFX, introduced in 2019, has shown promise with two ongoing NASH trials and three all-time trials dedicated to this condition. Similarly, empagliflozin, which made its debut in 2015, is also being explored through two active NASH trials and boasts an impressive record of eight all-time NASH studies. These innovative therapies offer hope for patients battling this complex liver disease as scientists continue to uncover potential breakthroughs.
What are the most recent clinical trials for nash?
Exciting advancements are being made in the field of nash treatment, with recent clinical trials offering hope and potential solutions for patients. One such trial is Part 1 Group 2, a Phase 2 study that aims to evaluate the efficacy and safety of a new intervention for nash. Additionally, BI 3006337 dose group 4, a Phase 1 trial, has shown promise as a potential treatment option for this condition. Pemvidutide at a dosage of 1.2 mg has also demonstrated positive outcomes in Phase 2 studies with nash patients. Furthermore, efinopegdutide at a dosage of 4mg is currently undergoing Phase 2 trials to assess its effectiveness against nash. Finally, TVB-2640 at a dosage of50 mg holds potential as an intervention for individuals with normal hepatic function affected by nash.This ongoing research offers renewed optimism to those living with this challenging disease
What nash clinical trials were recently completed?
In recent years, numerous clinical trials have been completed in the search for effective treatments for nonalcoholic steatohepatitis (NASH). Notable trials include Altimmune's investigation of ALT-801, which concluded in September 2021 and March 2022. Likewise, 89bio's trial on BIO89-100 and Merck Sharp & Dohme Corp.'s study on Efinopegdutide were both finalized in August 2021. Other studies such as Amgen's AMG 609 trial, Terns' TERN-201 trial, and Pfizer's PF-06865571 trial reached completion between May to August of 2021. These groundbreaking efforts highlight the collective commitment towards advancing NASH therapeutics and offer hope for patients grappling with this complex condition.